2012-10-05 16:56:54 - Recently published research from Global Markets Direct, "Fracture - Pipeline Review, H2 2012", is now available at Fast Market Research

Global Markets Direct's, 'Fracture - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Fracture, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fracture. Fracture - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Full Report Details at

- www.fastmr.com/prod/468412_fracture_pipeline_review_h2_2012.aspx


Scope

* A snapshot of the global therapeutic scenario for Fracture.
* A review of the Fracture products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Fracture pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Fracture.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Fracture pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Fracture Overview
Therapeutics Development
An Overview of Pipeline Products for Fracture
Fracture Therapeutics under Development by Companies
Fracture Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Fracture Therapeutics - Products under Development by Companies
Fracture Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Fracture Therapeutics Development
Amgen Inc.
Eli Lilly and Company
Kaken Pharmaceutical Co.,Ltd.
KOLON LIFE SCIENCE INC.
TissueGene, Inc.
Radius Health, Inc.
Fracture - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
romosozumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LY-333334 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KUR-111 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KCB-1B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
teriparatide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
testosterone enanthate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KUR-113 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous Mesenchymal Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KLS-Bfr - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Platelet Rich Plasma + Autologous Bone Marrow Aspirate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OsteoStem - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TG-B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fracture Therapeutics - Drug Profile Updates
Fracture Therapeutics - Discontinued Products
Fracture Therapeutics - Dormant Products
Fracture - Product Development Milestones
Featured News & Press Releases
Aug 07, 2012: Lilly Announces Study Results Regarding Postmenopausal Women With Back Pain Caused By Vertebral Fractures
Jul 03, 2012: Ibuprofen Improves Bone Repair After Surgery Or Fracture, Study Demonstrates
Jan 24, 2011: Kuros Reports One Year Data From Phase IIb Study With KUR-111
Jun 08, 2010: GTx Announces Toremifene 80mg Treatment Demonstrated Improved Fracture Reduction And Safety Profile In Men With Prostate Cancer On ADT Younger Than Age 80
Jun 02, 2010: Kuros Completes Patient Recruitment In A Phase IIB Trial Of KUR-113 In Patients With Tibial Shaft Fractures
Jun 01, 2010: Amgen Receives FDA Approval For Prolia For Treatment Of Postmenopausal Women With Osteoporosis At High Risk For Fracture

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468412&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.